Comparative Pharmacology
Head-to-head clinical analysis: BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER versus COREG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER versus COREG.
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER vs COREG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors.
Carvedilol is a nonselective beta-blocker with alpha1-blocking activity. It competitively blocks beta1, beta2, and alpha1 adrenergic receptors, leading to decreased cardiac output, reduced sympathetic tone, and vasodilation. It also has antioxidant and anti-proliferative properties.
Intravenous: For stable patients, an initial loading dose of 500 mcg/kg/min over 1 minute followed by a maintenance infusion of 50 mcg/kg/min for 4 minutes; if response is inadequate, increase maintenance infusion to 100 mcg/kg/min and repeat loading dose after 10 minutes. Titrate in 50 mcg/kg/min increments up to 200 mcg/kg/min. For intraoperative and postoperative use, see full prescribing information.
Heart failure: Start 3.125 mg orally twice daily; titrate up to target 25 mg twice daily as tolerated. Hypertension: Start 6.25 mg orally twice daily; increase to max 50 mg twice daily. Post-MI LV dysfunction: Start 3.125-6.25 mg orally twice daily; titrate to target 25 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 9 minutes (range 8–10 minutes). Clinically, the half-life is consistent with rapid offset of effect upon discontinuation; steady state is achieved within 30 minutes of continuous infusion.
Terminal elimination half-life is 7-10 hours in most patients, but may be prolonged in severe hepatic impairment (up to 14-18 hours). The half-life is not significantly altered in renal impairment.
Primarily metabolized by red blood cell esterases; <1% excreted unchanged in urine. Elimination is not dependent on renal or hepatic function.
Renal excretion of unchanged drug and metabolites accounts for approximately 16% of the dose; fecal excretion accounts for about 84% (mainly as metabolites). Less than 2% is excreted unchanged in urine.
Category C
Category C
Beta-Blocker
Beta-Blocker